Member Info for Botski2

A big delayed trade holding us back... never seen 3 mill in volume and no sp movement here before...

Ruck, I was referring to the future not the past, and simply suggesting that they look at some of the details and not just blindly jump on the band wagon. Nobody knows or can predict when or if Scancell will be bought out, so if you want to be in for when (or if) that happens, you're only option is to hold, or at least develop a core holding.

There are a lot of video online explaining what Scancell does, how the science works and the incredible results they've had to date. The more you read and watch, the more you'll understand that the buy and hold strategy is far more likely to reap rewards for you than trading in and out. There's only a couple of months until the trial data which could be (and all indications are that it will be) exceptional. How much better to already be in when that RNS lands?!

Nevermind not never-ending

Lol some of us have been persisting for 15 years... never-ending 15 minutes

Great to see a more proactive approach to shareholder comms: https://www.linkedin.com/posts/scancell-limited_cancerresearch-immunooncology-biotech-activity-7317531907263455233-TFjR?utm_source=share&utm_medium=member_desktop&rcm=ACoAABL_AmYBwACGupf_7VfO2jc-rbEES7Bj6PE

They must be really loving the pre clinical data on the lead antibody to be so determined to develop that in house. Previously the talk had all been about focus on Scib and Modi, and potentially out-licensing the antibody, so that must bode well, especially as we already have the cash to develop it.

Does this pave the way for the registration trial to be done in the UK only at a fraction of the cost?

Marta Lesko is head of global Business Development for immunology and neurology for Merck KGAA. Come on Phil!

It's night and Day from Cliff's first presentation

Much improved slide design

Another 20K for me :)

Announces Russia have developed a cancer vaccine they are going to roll out for free (in Russia).

Wonder what will happen to all the money that doesn't get taken up in the retail offer!? Most people who would have bought at 10.5 are still gonna buy at 11.15... imo

Bermuda, saying you're funded until a set point doesn't mean you leave the fund raising until that point, otherwise the share price would deteriorate far further than 10.5p. I'm surprised people can't see that the company needed to present as strong a case as possible to new investors, so the results and genmab deal are great proof points. If they left it later and later the price would continue to drop as all investors realise a placing was coming.

$1.2B not $1.2M Bob ;) post rec though

No details on the upfront

To bang the drum" JMC

Why is CT saying we should be looking at $100M up front for this when Lindy has said all upfronts on these will be of a similar order of magnitude to the Genmab deal?

When you refer to "one getting confused if a partial response is 70%, 70% being the target." I think you are referring to my question around the average size of response among responders 71% rather than the average number of people who have responded 86%. My question was around the correlation between the size of tumour reduction and overall survival, which Lindy confirmed correlated. Apologies if you were talking about someone elses question.